| Code | CSB-RA025141MB12HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to STSA-1201, targeting thymic stromal lymphopoietin (TSLP), a critical epithelial-derived cytokine that plays a central role in initiating and sustaining type 2 inflammatory responses. TSLP is produced by epithelial cells in response to environmental triggers, allergens, and tissue damage, where it activates dendritic cells and drives the differentiation of naive T cells toward a Th2 phenotype. Elevated TSLP expression has been implicated in the pathogenesis of multiple allergic and inflammatory conditions, including asthma, atopic dermatitis, chronic rhinosinusitis, eosinophilic esophagitis, and chronic obstructive pulmonary disease, making it an important therapeutic target for type 2 inflammation.
STSA-1201 serves as the reference antibody for this biosimilar product, providing researchers with a reliable tool for investigating TSLP-mediated signaling pathways and inflammatory mechanisms. This antibody is suitable for studies examining TSLP biology, epithelial-immune cell interactions, and the development of therapeutic strategies targeting type 2 inflammation in various disease models.
There are currently no reviews for this product.